Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENTPD1/CD39 is a cell surface enzyme that catalyzes the hydrolysis of nucleoside triphosphates (NTPs) and diphosphates (NDPs), such as ATP and ADP, to their corresponding monophosphates (AMP). It plays a critical role in modulating immune cell chemotaxis, regulating vascular endothelial function, preventing desensitization of platelet receptors, and generating extracellular adenosine.
Hydrolyzes extracellular ATP and ADP to AMP, ultimately leading to adenosine production.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ecto-nucleoside triphosphate diphosphohydrolase 1 (ENTPD1).